KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to -$414.0 million.

  • Amgen's Cash from Investing Activities fell 9714.29% to -$414.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year increase of 9404.32%. This contributed to the annual value of -$1.0 billion for FY2024, which is 9600.82% up from last year.
  • Amgen's Cash from Investing Activities amounted to -$414.0 million in Q3 2025, which was down 9714.29% from -$389.0 million recorded in Q2 2025.
  • In the past 5 years, Amgen's Cash from Investing Activities registered a high of $1.4 billion during Q1 2023, and its lowest value of -$27.1 billion during Q4 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$262.0 million (2023), whereas its average is -$1.8 billion.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 141000.0% in 2022, then surged by 132342.34% in 2023.
  • Quarter analysis of 5 years shows Amgen's Cash from Investing Activities stood at -$230.0 million in 2021, then crashed by 1410.0% to -$3.5 billion in 2022, then plummeted by 679.99% to -$27.1 billion in 2023, then soared by 98.52% to -$402.0 million in 2024, then decreased by 2.99% to -$414.0 million in 2025.
  • Its Cash from Investing Activities stands at -$414.0 million for Q3 2025, versus -$389.0 million for Q2 2025 and -$447.0 million for Q1 2025.